Open AccessImplementation of immunotherapy into the treatment of neuroblastoma – single center experience with the administration of dinutuximab and management of its adverse effects
Author(s) -
Monika Achbergerová,
Stanislava Hederová,
Martina Mikesková,
Kristína Husáková,
Andrea Hrašková,
Alexandra Kolenová
Publication year - 2020
Publication title -
klinická onkologie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.204
H-Index - 13
eISSN - 1802-5307
pISSN - 0862-495X
DOI - 10.14735/amko2020372
Subject(s) - adverse effect , immunotherapy , administration (probate law) , medicine , single center , center (category theory) , oncology , cancer , political science , chemistry , law , crystallography
Neuroblastoma is the most common extracranial solid tumour of childhood with extremely heterogeneous bio-logical and clinical behaviour. Despite advances in its treatment, the long-term prognosis of patients with a high-risk and relapsed neuroblastoma remains poor. The implementation of immunotherapy into the treatment protocols has the potential to improve it. Dinutuximab, a chimeric monoclonal antibody, leads to the apoptosis of tumour cells through binding to the GD2 receptor. The article aim is to present the first experience of our centre with dinutuximab treatment.